Cover Image

Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin

<p>Abstract</p> <p>Background</p> <p>Resistance to current chemotherapeutic agents is a major cause of therapy failure in ovarian cancer patients, but the exact mechanisms leading to the development of drug resistance remain unclear.</p> <p>Methods</p>...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sherman-Baust Cheryl A (Author), Becker Kevin G (Author), Wood III William H (Author), Zhang Yongqing (Author), Morin Patrice J (Author)
Format:	Book
Published:	BMC, 2011-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells
by: Sung-How Sue, et al.
Published: (2024)

Non-Steroidal Anti-Inflammatory Drugs Increase Cisplatin, Paclitaxel, and Doxorubicin Efficacy against Human Cervix Cancer Cells
by: Diana Xochiquetzal Robledo-Cadena, et al.
Published: (2020)

Evaluation of Pegylated Liposomal Doxorubicin in the Treatment Of Both Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer
by: Hao Lin, et al.
Published: (2004)

Survival and Side Effects of Cisplatin/Cyclophosphamide and Carboplatin/Paclitaxel Adjuvant Chemotherapy in Stage IC-IV Ovarian Cancer
by: Unedo H Markus, et al.
Published: (2015)

Remote loading paclitaxel-doxorubicin prodrug into liposomes for cancer combination therapy
by: Jiang Yu, et al.
Published: (2020)

Preparation and characterization of an injectable thermosensitive hydrogel for simultaneous delivery of paclitaxel and doxorubicin
by: Mahboubeh Rezazadeh, et al.
Published: (2018)

The effect of iron on the expression levels of calcium related gene in cisplatin resistant epithelial ovarian cancer cells
by: Bahire Kucukkaya, et al.
Published: (2021)

Sulforaphane Potentiates Anticancer Effects of Doxorubicin and Cisplatin and Mitigates Their Toxic Effects
by: Cinzia Calcabrini, et al.
Published: (2020)

Doxorubicin-induced ovarian toxicity
by: Rizel Shulamith, et al.
Published: (2010)

Clinical trials and progress with paclitaxel in ovarian cancer
by: Sanjeev Kumar, et al.
Published: (2010)

Severe hypertriglyceridemia during treatment with intraperitoneal cisplatin and paclitaxel for advanced stage fallopian tube carcinoma
by: Megan Lander, et al.
Published: (2020)

Cisplatin and paclitaxel co-delivered by folate-decorated lipid carriers for the treatment of head and neck cancer
by: Jiying Yang, et al.
Published: (2017)

Physiologically‐based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk
by: David Damoiseaux, et al.
Published: (2023)

Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy
by: Yongshuang Li, et al.
Published: (2020)

Carborane-Based ABCG2-Inhibitors Sensitize ABC-(Over)Expressing Cancer Cell Lines for Doxorubicin and Cisplatin
by: Svetlana Paskas, et al.
Published: (2023)

Pegylated liposomal doxorubicin in ovarian cancer
by: Robert Strother, et al.
Published: (2009)

Comparison of Antiemetic Effects of Ondansetron, Granisetron and Tropisetron in Treatment of Acute Emesis Caused By Cisplatin/Paclitaxel Chemotherapy
by: Taner Turan, et al.
Published: (2016)

TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel
by: Wardhani BWK, et al.
Published: (2020)

Adipose-Derived Stem Cells Primed with Paclitaxel Inhibit Ovarian Cancer Spheroid Growth and Overcome Paclitaxel Resistance
by: Cinzia Borghese, et al.
Published: (2020)

Bioinformatics analysis of gene expression profile of serous ovarian carcinomas to screen key genes and pathways
by: Hongjun Fei, et al.
Published: (2020)

Pegylated liposomal doxorubicin in the management of ovarian cancer
by: Gabriella Ferrandina, et al.
Published: (2010)

Growth Inhibition of Triple-Negative Breast Cancer: The Role of Spatiotemporal Delivery of Neoadjuvant Doxorubicin and Cisplatin
by: Dominick Salerno, et al.
Published: (2021)

The effect of paclitaxel- and fisetin-loaded PBM nanoparticles on apoptosis and reversal of drug resistance gene ABCG2 in ovarian cancer
by: Melayshia McFadden, et al.
Published: (2023)

Long-Circulating and Fusogenic Liposomes Loaded with Paclitaxel and Doxorubicin: Effect of Excipient, Freezing, and Freeze-Drying on Quality Attributes
by: Marjorie Roque, et al.
Published: (2022)

Selected phenotypic and functional changes in ovarian cancer cells treated in vitro with combined therapy using cisplatin and hyperthermia
by: Aleksandra Zoń, et al.
Published: (2023)

Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells
by: Yen-Ying Ma, et al.
Published: (2011)

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery
by: Sally Mullany, et al.
Published: (2020)

Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients
by: Zhenhua Du, et al.
Published: (2015)

Intensified dose-dense neoadjuvant chemotherapy using paclitaxel-gemcitabine and docetaxel-doxorubicin combinations for locally advanced breast cancer
by: I. V. Frai, et al.
Published: (2014)

Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancer
by: Taryne Chong, et al.
Published: (2018)

Analysis of the toxicity induced by carboplatin and paclitaxel regimen in ovarian cancer patients
by: Thaís A. GOUVÊA, et al.
Published: (2022)

Paclitaxel-Induced Hepatotoxicity in Ovarian Cancer Patients: A Case Report
by: Haoran Yang PharmD, et al.
Published: (2024)

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
by: Zhen Yuan, et al.
Published: (2021)

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in a woman with pseudomyxoma peritonei: A case report
by: Clemens B. Tempfer, et al.
Published: (2014)

Enhancement of Cisplatin Sensitivity by Microwave Radiation in Ovarian Cancer Cells
by: Mansour Tayebi-khorami, et al.
Published: (2022)

Circular RNA circTNPO3 Regulates Paclitaxel Resistance of Ovarian Cancer Cells by miR-1299/NEK2 Signaling Pathway
by: Bing Xia, et al.
Published: (2020)

Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy
by: Hyejeong Hue, et al.
Published: (2019)

Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II-III triple-negative breast cancer
by: O. O. Gordeeva, et al.
Published: (2020)

Comprehensive analysis of hub genes associated with cisplatin-resistance in ovarian cancer and screening of therapeutic drugs through bioinformatics and experimental validation
by: Yunshan Zhu, et al.
Published: (2024)

The PAPSS1 gene is a modulator of response to cisplatin by regulating estrogen receptor alpha signaling activity in ovarian cancer cells
by: Lei Sun, et al.
Published: (2023)